Shows that red ginseng extract alleviates inflammation in mice with colitis, suggesting therapeutic potential.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by recurrent intestinal inflammation and mucosal injury. This study evaluated the protective potential of red ginseng ethanolic extract (RGEE) using a dextran sulfate sodium (DSS)-induced colitis mouse model and an LPS-stimulated RAW 264.7 macrophage model. Preliminary LC-MS profiling was also performed to characterize the detectable chemical features of RGEE. In vivo, RGEE alleviated DSS-induced body weight loss, disease activity, colon shortening, spleen enlargement, and histopathological injury, with the histopathological score reduced by approximately 51.1%. RGEE also partially improved DSS-induced hematological alterations without causing obvious changes in major organ weights. In vitro, RGEE showed no obvious cytotoxicity up to 250 μg/mL and reduced LPS-induced NO, TNF-α, IL-6, and IL-1β production by approximately 60.0–67.1%. LC-MS analysis putatively annotated several saponin-related features, including notoginsenoside R1 and ginsenosides Rb1, Rb2, Rh1, Rh4, and Rh2. These findings suggest that RGEE has protective potential against DSS-induced colitis, which is associated with the suppression of inflammatory mediator production. Further studies are needed to clarify its active constituents and mechanisms of action.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: